A Phase I Open-label Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of AK127 Monotherapy in Patients With Advanced Malignant Tumors
Latest Information Update: 07 Jun 2024
At a glance
- Drugs AK 127 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Akeso Biopharma
Most Recent Events
- 01 Jun 2022 New trial record